CVS Health Corporation $CVS Shares Sold by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC lowered its holdings in CVS Health Corporation (NYSE:CVS) by 3.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,585 shares of the pharmacy operator’s stock after selling 280 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in CVS Health were worth $523,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in CVS Health by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock valued at $8,017,223,000 after purchasing an additional 969,027 shares in the last quarter. Dodge & Cox grew its stake in shares of CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after buying an additional 3,353,223 shares in the last quarter. Invesco Ltd. raised its holdings in shares of CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after buying an additional 2,375,764 shares during the period. Price T Rowe Associates Inc. MD lifted its position in CVS Health by 14.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock worth $1,037,205,000 after acquiring an additional 1,942,886 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in CVS Health by 5.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock worth $924,643,000 after acquiring an additional 728,924 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 0.8%

Shares of CVS Health stock opened at $77.48 on Friday. The business has a 50-day moving average price of $70.37 and a 200 day moving average price of $67.27. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $77.76. The firm has a market cap of $98.27 billion, a P/E ratio of 21.64, a P/E/G ratio of 0.85 and a beta of 0.60. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping the consensus estimate of $1.46 by $0.35. The company had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s payout ratio is presently 74.30%.

Insider Activity

In other news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.22% of the company’s stock.

Analysts Set New Price Targets

CVS has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Sunday, September 21st. Sanford C. Bernstein boosted their price objective on shares of CVS Health from $72.00 to $77.00 and gave the stock a “market perform” rating in a report on Friday, September 5th. Barclays raised their target price on CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, September 4th. UBS Group upgraded CVS Health from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $67.00 to $79.00 in a research note on Monday, August 18th. Finally, Robert W. Baird upgraded CVS Health from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $78.25.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.